Figure 4 | Scientific Reports

Figure 4

From: Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Figure 4

The secondary T790M rate between patients grouped by (A) with or without BM and PFS ≥ or < 12 months (B) with or without BM, EGFR mutation subtype and generation of EGFR-TKI treatment. BM brain metastasis, 19del EGFR 19 deletion mutation, L858R EGFR L858R mutation, 1G first-generation EGFR-TKI, 2G second-generation EGFR-TKI.

Back to article page